Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Chirality in Nature02:30

Chirality in Nature

Chirality is the most intriguing yet essential facet of nature, governing life’s biochemical processes and precision. It can be observed from a snail shell pattern in a macroscopic world to an amino acid, the minutest building block of life. Most of the snails around the world have right-coiled shells because of the intrinsic chirality in their genes. All the amino acids present in the human body exist in an enantiomerically pure state, except for glycine - the sole achiral amino acid. The...
Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Klinefelter syndrome in a Holstein-Friesian bull: a case report.

Irish veterinary journal·2026
Same author

Performance Optimization of a Large Geometry High Resolution-Secondary Ion Mass Spectrometer (HR-SIMS) for High Precision Measurements of Oxygen Isotopic Composition (δ<sup>18</sup>O) and U-Pb Geochronology in Zircon.

Journal of mass spectrometry : JMS·2024
Same author

Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR).

Annals of clinical microbiology and antimicrobials·2022
Same author

Metagenomic assembled plasmids of the human microbiome vary across disease cohorts.

Scientific reports·2022
Same author

Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease.

Nature communications·2020
Same journal

Eravacycline in sepsis complicated by <i>Clostridioides difficile</i> infection: a brief case series.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Apatinib combined with capecitabine plus temozolomide versus sunitinib in advanced gastroenteropancreatic neuroendocrine tumours: a propensity score-matched real-world study.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Pharmacokinetic/pharmacodynamic optimization of antimicrobial therapy in neutropenic sepsis: a comprehensive review.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Cefiderocol for <i>Stenotrophomonas maltophilia</i> infections: real-world evidence from a multicenter study and a comprehensive literature review.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Cefiderocol susceptibility in carbapenem-resistant <i>Acinetobacter baumannii</i>, <i>Pseudomonas aeruginosa</i>, and <i>Stenotrophomonas maltophilia</i> isolates: concordance of disk diffusion with the reference method and comparative analysis of CLSI-EUCAST criteria.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

High-dose continuous infusion of piperacillin/tazobactam via elastomeric pump in a pediatric patient with Kartagener syndrome: pharmacokinetic target attainment and clinical outcome.

Journal of chemotherapy (Florence, Italy)·2026
See all related articles

Related Experiment Video

Updated: May 26, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

Echinocandins: are they all the same?

P K Mukherjee1, D Sheehan, L Puzniak

  • 1Center for Medical Mycology and Mycology Reference Laboratory, Department of Dermatology, University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, Ohio 44106, USA.

Journal of Chemotherapy (Florence, Italy)
|January 12, 2012
PubMed
Summary
This summary is machine-generated.

Echinocandins are vital antifungals, but distinct differences exist between anidulafungin, caspofungin, and micafungin. Further research is needed to explore potential clinical advantages of these variations.

More Related Videos

Quantifying the Antifungal Activity of Peptides Against Candida albicans
06:45

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

Related Experiment Videos

Last Updated: May 26, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

Quantifying the Antifungal Activity of Peptides Against Candida albicans
06:45

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

Area of Science:

  • Pharmacology
  • Mycology
  • Infectious Diseases

Background:

  • Echinocandins represent a crucial class of antifungals, expanding treatment options beyond traditional polyenes and azoles.
  • Three echinocandins—anidulafungin, caspofungin, and micafungin—are FDA-approved for treating fungal infections.
  • Despite a shared mechanism targeting the fungal cell wall, these echinocandins are often perceived as therapeutically equivalent.

Purpose of the Study:

  • To conduct a scientific literature review comparing the distinct properties of anidulafungin, caspofungin, and micafungin.
  • To identify and analyze differences in in vitro activity, fungicidal effects, post-antifungal effects, paradoxical effects, and biofilm activity among the three echinocandins.

Main Methods:

  • Comprehensive review of existing scientific literature on echinocandins.
  • Comparative analysis of in vitro and in vivo data for anidulafungin, caspofungin, and micafungin.

Main Results:

  • The literature review revealed significant variations among the echinocandins.
  • Key differences were observed in their in vitro activity spectrum, fungicidal potency, and post-antifungal effect duration.
  • Distinct profiles were also noted regarding paradoxical effects and efficacy against fungal biofilms.

Conclusions:

  • Echinocandins, while sharing a common structural backbone and mechanism of action, exhibit notable inter-drug differences.
  • These variations in pharmacological and microbiological properties warrant further investigation.
  • Determining whether these identified differences translate into tangible clinical benefits is a critical next step for optimizing antifungal therapy.